title: High-density lipoprotein profiling changes in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a cohort study.
abstract: OBJECTIVE
  We investigated changes in high-density lipoprotein (HDL) profiling in patients with rheumatoid arthritis who started treatment by taking tumor necrosis factor (TNF) inhibitors. The patients were stratified for European League Against Rheumatism (EULAR) response.
  
  
  METHODS
  A group of 100 patients naive for TNF inhibitors at baseline were randomly selected from 204 adalimumab-treated and 203 etanercept-treated patients on the basis of their EULAR response. HDL profiling was measured using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
  
  
  RESULTS
  In EULAR good responders, mass charged markers representing serum amyloid A (SAA-1 and -2) decreased significantly after 4 months' therapy. There were no significant differences in HDL profiling in EULAR nonresponders.
  
  
  CONCLUSIONS
  Effective suppression of inflammation with TNF inhibitors results in favorable changes in HDL composition.
authors: Jan van Breemen Research Institute, Amsterdam, The Netherlands.
authors: Anna
authors: A
authors: Jamnitski
authors: Johannes H
authors: JH
authors: Levels
authors: Inge A
authors: IA
authors: van den Oever
authors: Michael T
authors: MT
authors: Nurmohamed
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000188:drug therapy; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D008075:Lipoproteins, HDL; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D000068800:Etanercept; D008727:Methotrexate
keywords: CARDIOVASCULAR RISK; HIGH-DENSITY LIPOPROTEINS; LIPID PROFILE; RHEUMATOID ARTHRITIS; TUMOR NECROSIS FACTOR INHIBITORS